1636

OCT 0 2 2002

**POCKET NO.: SMAR-0013** 

TECH CENTER 1600/2900

**PATENT** 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Michael R. Hayden, et al.

Serial No.: 10/019,341

Filing Date: May 3, 2002

Group Art Unit: Not Yet Assigned

**Examiner: Not Yet Assigned** 

For: LPL VARIANT THERAPEUTICS

DATE OF DEPOSIT: September 26, 2002

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASTINGTON, DC 20231.

TYPED NAME: Phillip A. Singer REGISTRATION NO.: 40,176

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

#### INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being

filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

•

DOCKET NO	O.: SMAR-0013 - 2 - PATENT
	In accordance with §1.129(a), this Information Disclosure Statement is bein
	filed in connection with $\square$ the first or $\square$ second After Final Submission
	therefore:
	☐ Certification in Accordance with §1.97(e) is attached; or
	The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.
	In accordance with §1.97(c), this Information Disclosure Statement is being file
•	after the period set forth in §1.97(b) above but before the mailing date of either
	a Final Action under §1.113 or a Notice of Allowance under §1.311, or before a
	action that otherwise closes prosecution in the application, therefore:
	☐ Certification in Accordance with §1.97(e) is attached; or
	The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.
	In accordance with §1.97(d), this Information Disclosure Statement is being file
	after the mailing date of either a Final Action under §1.113 or a Notice of
	Allowance under §1.311 but before, or simultaneously with, the payment of the
	Issue Fee, therefore included are: Certification in Accordance with §1.97(e); an
	the submission fee of \$180.00 as set forth in \$1.17(p).
$\boxtimes$	Copies of each of the references listed on the attached Form PTO-1449 ar
	enclosed herewith.
	Copies of references listed on the attached Form PTO-1449 are enclosed herewit
	EXCEPT THAT:
	In view of the voluminous nature of references 11, 38,53,108,, and the
	likelihood that these references are available to the Examiner, copies ar
	not enclosed herewith.

DOCKET NO.: SM	AR-0013	- 3 -				PATE	NT
	In accorda	ance with §1.98(d),	copies of the	following	reference	es listed	l on
	the attache	ed Form PTO-1449	are not enclos	sed herewit	th because	e they w	ere
	previously	y cited by or submit	ted to the U.S	. Patent an	d Tradem	ark Of	fice
	in patent	application(s) for	r which a c	laim for	priority	under	35
	U.S.C.§12	20 have been made	in the instant	application	n:		
	Copies of	references [list as	appropriate	] listed on	the attac	hed Fo	orm
	PTO-1449	were previously	cited by or	submitted	to the l	Patent	and
	Trademar	k Office in prior ap	plication Seri	ial No.	, filed		
	□ If	any of the forego	ing publicati	ons are n	ot availa	ble to	the
	Ex	aminer, Applicant	will endeav	vor to sup	pply cop	ies at	the
	Ex	caminer's request.					

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: September 26, 2002

Phillip A. Singer

Registration No. 40,176

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2001 WW

OCT 0 2 2002

# TECH CENTER 1600/2900

Sheet 1 of 15

PRADEM Orm PTO-1449 Modified	Docket No. SMAR-0013	Serial No. 10/019,341		
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	Applicant Hayden, M.R. e	t al.		
U.S. Department of Commerce Patent and Trademark Office	Filing Date May 3, 2002	Group Not Yet Assigned		
OTHER DOCUMENTS (Including Aut	hor, Title, Date, Per	tinent Pages, Etc.)		
1 Ascadi, G. et al., "Human dystrop injection of DNA constructs", Nat	<u>-</u>			
2 Altschul, S.F. et al., "Basic Local 403-410	Alignment Search To	ol", J. Mol. Biol., 1990, 215,		
3 Anderson, W. F., "The Best of Tin 629	nes, the Worst of Tin	nes", <i>Science</i> , <b>2000</b> , 288, 627-		
Retrovirus-Mediated Gene Transf	Armentano, D. et al., "Expression of Human Factor IX in Rabbit Hepatocytes by Retrovirus-Mediated Gene Transfer: Potential for Gene Therapy of Hemophilia B", <i>Proc. Natl. Acad. Sci. USA</i> , <b>1990</b> , 87, 6141-6145			
5 Assmann, G. MD. et al., "Relation Triglycerides to Incidence of Athe Experience)", Am. J. Cardiol., 199	erosclerotic Coronary			
6 Baldari, et al., "A novel leader per interleukin 1β in Saccharomyces of		<del>-</del>		
7 Baliga, et al., "High fat meal induction coronary artery disease", 70th Scie				
8 U. Beisiegel, "Lipoprotein Metabo A23				
chylomicronemia caused by muta	9 Benlian, P. MD., Ph.D. et al., "Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene", <i>The New England Journal of Medicine</i> , 1996, 335, 848-854			
Berkner, K.L. "Development of Adenovirus Vectors for the Expression of Heterologous Genes", <i>BioTechniques</i> , 1988, 6(7), 616-629				
EXAMINER DATE CONSIDERED				

OCT 0 2 2002

TECH CENTER 1600/2900 Sheet 2 of 15 Form PTO-1449 Modified Docket No. Serial No. **SMAR-0013** 10/019,341 List of Patent and Publications Applicant Cited by Applicant Hayden, M.R. et al. (Use several sheets if necessary) U.S. Department of Commerce Filing Date Group Patent and Trademark Office May 3, 2002 Not Yet Assigned OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Bethesda: Lipids Research Clinics Program, NIH(National Institute of Health) Publication, 1974, Vol 75 Black, M.E. et al., "Creation of Drug-Specific Herpes Simplex Virus Type 1 12 Thymidine Kinase Mutants for Gene Therapy", Proc. Natl. Acad. Sci. USA, 1996, 93, 3525-3529 Brunzell, J.D. et al., "Structure-function relationships of lipoprotein lipase: mutation 13 analysis and mutagenesis of the loop region", Journal of Lipid Research, 1993, 34, (9), 1593-1602 Brunzell, J.D. "Familial Lipoprotein Lipase Deficiency and Other Causes of the 14 Chylomicronemia Syndrome", The Metabolic and Molecular Bases of Inherited Disease, New York, NY, McGraw-Hill, Inc., 1995, 59, 1913-1932 Cavazzana-Calvo, M. "Gene Therapy of Human Severe Combined Immunodeficiency 15 (SCID)-X1 Disease", Science, 2000, 288, 669-672 16 Chowdhury, J.R, et al., "Long-Term Improvement of Hypercholesterolemia After ex Vivo Gene Therapy in LDLR-Deficient Rabbits", Science, 1991, 254, 1802-1805 Clapp, D.W. et al., "Fetal Liver Hematopoietic Stem Cells As a Target for In Utero 17 Retroviral Gene Transfer", Blood, 1991, 78, 1132-1139 Cohen, J.C. et al., "Postprandial lipemia and chylomicron clearance in athletes and in 18 sedentary men", Am. J. Clin. Nutr., 1998, 49, 443-447 19 Cristiano, R.J. et al., "Hepatic Gene Therapy: Adenovirus Enhancement of Receptor-Mediated Gene Delivery and Expression in Primary Hepatocytes", Proc. Of the Nat'l Academy of Sciences, 1993, 90, 2122-2126 Curiel, D.T. et al., "Adenovirus Enhancement of Transferrin-Polylysine-Mediated 20 Gene Delivery", Proc. Natl. Acad. Sci. USA, 1991, 88, 8850-8854 **DATE CONSIDERED EXAMINER** 

<sup>\*</sup> A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

# SEP 3 0 2002 W

### RECEIVED

OCT 0 2 2002

## TECH CENTER 1600/2900

Sheet 3 of 15

Form Form	PTO-1449 Modified	Docket No. SMAR-0013	Serial No. 10/019,341	
	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Hayden, M.R. et al.		
	Department of Commerce nt and Trademark Office	Filing Date May 3, 2002	Group Not Yet Assigned	
ОТН	ER DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
21	Dai, Y. et al., "Gene Therapy Via Pri Factor IX Protein Following Transpla 1992, 89(22), 10892-10895		-	
22	Danos, O. et al., "Safe and Efficient of Amphotropic and Ecotropic Host Rai 6460-6464			
23	Davies, Michael J. MD. "Stability and Instability: Two Faces of Coronary Atherosclerosis: The Paul Dudley White Lecture 1995", <i>Circulation</i> , <b>1996</b> , 94(8), 2013-2020			
24	Eglitis, M.A. et al., "Gene Expression in Mice after High Efficiency Retroviral-Mediated Gene Transfer", <i>Science</i> , <b>1985</b> , 230, 1395-1398			
25	Eyre-Walker, A. et al., "High genome Nature, 1999, 397, 344-347	ic deleterious mutation	rates in hominids",	
26	Excoffon, K. J.D. et al., "Correction of Hypertriglyceridemia and Impaired Fat Tolerance in Lipoprotein Lipase-Deficient Mice by Adenovirus-Mediated Expression of Human Lipoprotein Lipase", Arterioscler. Thromb. Vasc. Biol., 1997, 17(11), 2532-2539			
27	Faure, L. et al, "Prevalence of commo Ser447Stop is increased while preval centenarians", Atherosclerosis, 1997,	ence of Asn291Ser mu		
. 28	Feinleib, M. et al., "The Framingham Prevent. Med., 1975, 4, 518-525	Offspring Study. Des	ign and Preliminary Data",	
. 29	Ferry, N. et al., "Retroviral-Mediated Gene Transfer Into Hepatocytes in vivo", 1991, 88(19), 8377-8381			
30	Fisher, R.M. et al., "Common variation in the lipoprotein lipase gene: effects on plasma lipids and risk of atherosclerosis", <i>Atherosclerosis</i> , <b>1997</b> , 135, 145-159			
EXAMINER		DATE CONSIDER	ED	

5	<u> </u>		~ <del>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</del>	Sheet 4 of 15		
TRADEMAN	Form	PTO-1449 Modified	Docket No. SMAR-0013	Serial No. 10/019,341		
		f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Hayden, M.R. et a	Applicant Hayden, M.R. et al.		
		Department of Commerce at and Trademark Office	Filing Date May 3, 2002	Group Not Yet Assigned		
	ОТНЕ	ER DOCUMENTS (Including Aut	nor, Title, Date, Pertin	ent Pages, Etc.)		
	31	Flotte, T.R. et al., "Gene Expression Epithelial Cells", Am. J. Respir. Co		<del>_</del>		
	32	Flotte, T.R. et al., "Expression of t Regulator from a Novel Adeno-ass 268(5), 3781-3790				
	33	Gagne, E. et al., "Analysis of DNA Familial Combined Hyperlipidemi	•			
	34	Gagne, SE. et al., "A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study", <i>Clin. Genet.</i> , <b>1999</b> , 55(6), 450-454				
	35	Garenc, C. et al., "Linkage and Association Studies of the Lipoprotein Lipase Gene with Postheparin Plasma Lipase Activities, Body Fat, and Plasma Lipid and Lipoprotein Concentrations: The HERITAGE Family Study", <i>Metabolism</i> , <b>2000</b> , 49(4), 432-439				
	36	Gaziano, J. MD et al., "Fasting Tri Myocardial Infarction", Circulatio		• • •		
	37	Gehrisch, S. MD., "Common Muta Clinical Significance", Curr. Ather		_		
*	38	Goeddel, Gene Expression Techno Academic Press, San Diego, Califo		nology, <b>1990</b> , vol 185,		
	39	Groenemeijer, B.E. MD. Et al., "Genetic Variant Showing a Positive Interaction with beta-Blocking Agents with a Beneficial Influence on Lipoprotein Lipase Activity, HDL Cholesterol, and Triglyceride Levels in Coronary Artery Disease Patients: The Ser sup 447-Stop Substitution in the Lipoprotein Lipase Gene", Circulation, 1997, 95(12), 2628-2635				
	Gronholdt, M-L M. MD. Et al., "Echo-Lucency of Computerized Ultrasound Image of Carotid Atherosclerotic Plaques are Associated with increased Levels of Triglyceride-Rich Lipoproteins as Well as Increased Plaque Lipid Content", Circulation, 1998, 97(1), 34-40					
EXAMI	NER		DATE CONSIDE	RED		

<sup>\*</sup> A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

OCT 0 2 2002

TECH CENTER 1600/2900

SEP 3 0 2002 4

Sheet 5 of 15

		10/019,341		
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)	Applicant Hayden, M.R. et al.	Applicant Hayden, M.R. et al.		
U.S. Department of Commerce Patent and Trademark Office	Filing Date May 3, 2002	Group Not Yet Assigned		
OTHER DOCUMENTS (Including Auth	or, Title, Date, Pertine	nt Pages, Etc.)		
Hamsten, A. MD. Et al., "Increased Plasminogen Activator in Young St Med., 1985, 313(25), 1557-1563	-			
Hasdai, D. MD. Et al., "Coronary E with Myocardial Perfusion Defects"	•			
Hayden, MR. Et al., "Gene environg crucial role of lipoprotein lipase", C	<del>-</del>			
Lipoprotein Lipase Gene Causes Li	Henderson, H.E. et al., "Amino Acid Substitution (lle 194THR) in Exon 5 of the Lipoprotein Lipase Gene Causes Lipoprotein Lipase Deficiency in Three Unrelated Probands", Journal of Clinical Investigation, 1991, 87, 2005-2011			
patients with coronary artery diseas	Henderson, H.E. et al., "Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins", <i>Journal of Lipid Research</i> , <b>1999</b> , 40, 735-743			
46 Henikoff, S. et al., "Amino Acid Su Natl. Acad. Sci. USA, 1992, 89(12),		n Protein Blocks", <i>Proc</i> .		
Cloning Vector: Transduction of No	Hermonat, P.L. et al., "Use of Adeno-Associated Virus as a Mammalian DNA Cloning Vector: Transduction of Neomycin resistance into Mammalian Tissue Culture Cells", <i>Proc. Natl. Acad. Sci. USA</i> , <b>1984</b> , 81(20), 6466-6470			
	Herz, J. et al., "Adenovirus-Mediated transfer of Low Density Lipoprotein Receptor Gene Acutely Accelerates Cholesterol Clearance in Normal Mice", <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90(7), 2812-2816			
49 Hexter, A. "Selective Advantage of	49 Hexter, A. "Selective Advantage of the Sickle-Cell Trait", Science, 1968, 160, 436			
Hodis, H.N. et al., "Triglyceride-rich lipoproteins and the progression of coronary artery disease", Curr. Opin. Lipid, 1995, 6, 209-214				
EXAMINER	DATE CONSIDER	ED		

#### OCT 0 2 2002

## **TECH CENTER 1600/2900**

Sheet 6 of 15

& TRADEMARK	Form	PTO-1449 Modified	Docket No. SMAR-0013	Serial No. 10/019,341	
		f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Hayden, M.R. et al.		
		Department of Commerce at and Trademark Office	Filing Date May 3, 2002	Group Not Yet Assigned	
	OTHE	CR DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)	
	51	Hokanson, J.E. "Lipoprotein lipase g quantitative analysis of population-b 34		<del>-</del>	
	52	Hokanson, J.E. et al., "Plasma trigly disease independent of high-density population-based prospective studies	lipoprotein cholesterol	level: a meta-analysis of	
*	53	Hosmer, et al., Applied Logistic Reg	ression, New York: Joh	n Wiley & Sons, <b>1989,</b> 1	
	54	Huber, B.E. et al., "Retroviral-Mediated Gene Therapy for the Treatment of Hepatocellular carcinoma: An Innovative Approach for Cancer Therapy", <i>Proc. I Acad. Sci. USA</i> , <b>1991</b> , 88, 8039-8043			
	55	Hwu, P. et al., "Functional and Mole Lymphocytes Transduced with Tumof Cancer in Humans", J. Immunol.,	or Necrosis Factor-α cl	_	
	56	Inoue, T. et al., "Serum Level of Rer Endothelium-Dependent Coronary V Sessions of the AHA, 2208			
	57	Jukema, J. et al., "Coronary Artery I Lowering by Pravastin on Progressic Symptomatic Men with Normal to M The Regression Growth Evaluation S 91(10), 2528-2540	on and egression of Co loderately Elevated Se	ronary Artery Disease in rum Cholesterol Levels:	
	58	<ul> <li>Jukema, J. et al., "Prevention of Cardiovascular Disease: The Asp sub 9 Asn Mutation in the Lipoprotein Lipase Gene is Associated with Increased Progression of Coronary Atherosclerosis", Circulation, 1996, 94(8), 1913-1918</li> <li>Kastelein, J.J.P. MD, PhD, et al., "Lipoprotein Lipase Activity is Associated with Severity of Angina Pectoris", Circulation, 2000, 102(14), 1629-1633</li> </ul>			
	59				
	60	Kaufman, R.J. et al., "Translational outilization to express heterologues go 187-193			
EXAMIN	ER		DATE CONSIDER	ED	
			1.		

<sup>\*</sup> A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

# SEP 3 0 2002 SEP 3 0 2002 SEP

### RECEIVED

OCT 0 2 2002

TECH CENTER 1600/2900

Sheet 7 of 15

Form PTO-1449 Modified  Docket No. Serial 10/019				
	7,341			
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  Applicant Hayden, M.R. et al.				
U.S. Department of Commerce Patent and Trademark Office Filing Date May 3, 2002 Not Y	et Assigned			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Page	s, Etc.)			
Kay, M.A. et al., "Hepatic Gene Therapy: Persistent Expression of Antitrypsin in Mice after Direct Gene Delivery In Vivo," Human G 1992, 3,641-647				
Keyt, B.A. et al., "A Faster-Acting and More Potent Form of Tissue Activator", <i>Proc. Natl. Acad. Sci. USA</i> , <b>1994</b> , 91(9), 3670-3674	e Plasminogen			
63 Khoury, et al., Fundamentals of Genetic Epidemiology: Oxford Unit Oxford, 1993, 49-54	iversity Press,			
	Regression Analysis and Other Multivariable Methods, 2 <sup>nd</sup> ed. Boston, MA: PWS-Kent			
65 Kramer, W. et al., "Liver-specific Drug Targeting by Coupling to B Chem., 1992, 267(26),18598-18604				
Krapp, A. et al., "Structural features in lipoprotein lipase necessary of lipoprotein uptake into cells", J. Lipid. Res., 1995, 36(11), 2362-				
Kugiyama, K. et al. "Remnant Lipoproteins Impair Endothelium-de Vasomotor Functions in Human Coronary Arteries", 70th Scientific AHA, 2207				
1 1	Kuivenhoven J.A. et al., "Ser 447stop Mutation in Lipoprotein Lipase Is Associated With Elevated Hdl Cholesterol Levels in Normolipidemic Males", <i>Arteriosclerosis, Thrombosis and Vascular Biology</i> , <b>1997</b> , 17, 595-599			
	Precursor Contains Four Tandem Copies of Mature α-Factor", Cell, 1982, 30, 933-			
	\$\alpha_1\$-Antitrypsin cDNA to Human Endothelial Cells", Proc. Natl. Acad. Sci.			
EXAMINER DATE CONSIDERED				

# OIPE 10,88

#### RECEIVED

OCT 0 2 2002

Sheet 8 of 15

FORM FORM	PTO-1449 Modified	2000 Decket No. SMAR-0013	Serial No. 10/019,341
	of Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Hayden, M.R. et al.	
	Department of Commerce nt and Trademark Office	Filing Date May 3, 2002	Group Not Yet Assigned
OTHI	ER DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)
71	Liu, M-S. Et al., "Mapping of the epi monoclonal antibody (%D2) which in 1992, 1128(1), 113-115		
72	Liu, G. et al., "Efficient Adenovirus- Lipoprotein Lipase in Human Hepati 205-214	_	-
73	Liu, G. et al., "Enhanced lipolysis in lipoprotein lipase after", Clin. Investigation	-	_
74	Liu, G. et al., "Phenotypic Correction of Feline Lipoprotein Lipase Deficiency by Adenoviral Gene Transfer", Hum. Gene. Ther., 2000, 11, 21-32		
75	Luckow, V.A. et al., "High Level Expression of Nonfused Foreign Genes with Autographa californica Nuclear Polyhedrosis Virus Expression Vectors", Virology, 1989, 170, 31-39		
76	Lundman, P. MD. Et al., "Transient Tyoung, Healthy Men Without Risk F 1997, 96(10), 3266-3268		
77	Ma, Y. et al., "Two Naturally Occurr Codon Aspartic Acid 156 in the Prop Lipase", J. Biol. Chem., 1992, 267(3)	osed Catalytic Triad o	
. 78	Ma, Y. et al., "Mutagenesis in four ca 282, 291-304, 390-393, and 439-448" binding of human lipoprotein lipase"	and identification of a	residues affecting heparin
. 79	Ma, Y. et al., "A Missense Mutation Lipoprotein Lipase Gene Causes Chy Ancestries", <i>Genomics</i> , <b>1992</b> , 13, 649	lomicronemia in Patie	
80	Ma, Y. et al., "A 4 basepair deletion results in type 1 hyperlipoproteinemia 1050		
EXAMINER		DATE CONSIDER	ED

OCT 0 2 2002

SEP 3 0 2002

TECH CENTER 1600/2900

Sheet 9 of 15

TRADEMARKS F	orm	PTO-1449 Modified	Docket No. SMAR-0013	Serial No. 10/019,341	
	(	Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Hayden, M.R. et al.		
		epartment of Commerce t and Trademark Office	Filing Date May 3, 2002	Group Not Yet Assigned	
. 0	THE	R DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
	81	Ma, Y. et al., "Gene-Environment Int Phenotype in a Patient Homozygous Lipase Gene", J. Clin. Invest, 1993, 9	for a Ser 172 Cys Muta		
·	82	Ma, Y. et al, "High frequency of muta pregnancy-induced chylomicronemia isoform", <i>J. Lipid. Res.</i> , <b>1994</b> , 35(6),	: possible association	1 0	
	83	Mailly, F. et al., "A Common Variant in the Gene for Lipoprotein Lipase (Asp9-Asn): Functional Implications and Prevalence in Normal and Hyperlipidemic Subjects", <i>Arterioscler. Thromb. Vasc. Biol.</i> , 1995, 15(4), 468-478			
	84	Marenberg, M.E. et al., "Genetic Suse in a Study of Twins", New Engl. J. M.		-	
	85		Mattei, M.G. et al., "Assignment of the human lipoprotein lipase (LPL) gene to chromosome band 8p22", Cytogenet Cell Genet, 1993, 63, 45-46		
	86	Angiographically Defined Severity of	at the LPL Gene Locus Associate with of Atherosclerosis and Serum Lipoprotein Levels erosis and Thrombosis, 1994, 14, 1090-1097		
	87	McLaughlin, S.K. et al., "Adeno-Asse Analysis of Proviral Structures", J. V.			
	88	Miller, A.D. "Progress Toward Huma	an Gene Therapy", Blo	od, <b>1990</b> , 76(2), 271-278	
	Monsalve, M.V. et al, "A Missense Mutation at Codon 188 of the Human Lipoprotein Lipase Gene Is a Frequent Cause of Lipoprotein Lipase Deficiency in Persons of Different Ancestries", J. Clin. Invest, 1990, 86(3), 728-734				
	Moss, J. "Peptide Prodrugs Designed to Limit Metabolism, Rationale and Applications of the Prodrug Concept for Pwptides", Peptide-Based Drug Design:  Controlling Transport and Metabolism, 1995, 18, 423-448				
EXAMINER			DATE CONSIDER	ED	

OCT 0 2 2002 TECH CENTER 1600/2900

Sheet 10 of 15

TRADEMARE	Form 1	PTO-1449 Modified	Docket No. SMAR-0013	Serial No. 10/019,341	
	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)				
		epartment of Commerce and Trademark Office	Filing Date May 3, 2002	Group Not Yet Assigned	
	OTHE	R DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
	91	Murthy, V. et al., "Molecular Pathol Pharmacol. Ther., 1996, 70(2), 101-		Lipoprotein Lipase Gene",	
	92	Muzyczka, N., "Use of Adeno-Asso for Mammalian Cells", Curr. Topics			
	93	Needleman, S.B. et al., "A General in the Amino Acid Sequence of Two			
	94		son-Ehle, P. et al., "A stable, radioactive substrate emulsion for assay of protein lipase", J. Lipid. Res., 1976, 17, 536-541		
	95	Olivecrona, G. et al., "Transport of Artherosclerosis X. Woodford et al,		lipoprotein metabolism",	
	96	Olivecrona, G. et al., "Noncatalytic Enzymol, 1997, 286, 102-116	functions of Lipoprote	in Lipase", Methods	
	97	Pearson, W.R. et al., "Improved Too Natl. Acad. Sci. USA., 1988, 85(8), 2	<del>-</del>	ence Comparasion", Proc.	
	98	(Asn291Ser) results in altered postp	tly occurring mutation in the lipoprotein lipase gene stprandial chylomicron triglyceride andretinyl emic carriers", <i>J. Lipid. Res.</i> , <b>1996</b> , 37, 1675-1684		
·	99	Quantin, B. et al., "Adenovirus as an Proc. Natl. Acad. Sci. USA, 1992, 89	an Expression Vecotr in Muscle Cells in vivo", 89(7), 2581-2584		
•	Quyyumi, A.A. et al., "Nitric Oxide Activity in the Human Coronary Circulation", Clin. Invest., 1995, 95, 1747-1755				
EXAMINER DATE CONSIDERED				ED	

OCT 0 2 2002

Form PTO-1449 Modified  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  101 Reichardt, J.K. V. et al., "Genetic Variability of the Human SRD5A2 Gene: Implications for Prostate Cancer Risk", Cancer Res., 1995, 55, 3973-3975  102 Renier, G. et al., "Lipoprotein Lipase Synergizes with Interferon Gamma to Induce Macrophage Nitric Oxide Synthetase mRNA Expression and Nitric Oxide Production", Arterioscler Thromb. Vasc. Biol., 1995, 15, 392-399  103 Reymer, P. W.A. et al., "A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis", Nat. Genet., 1995, 10, 28-33  104 Rosenfeld, M.A. et al., "Adenovirus-Mediated Transfer of a recombinant \$/alpha\$1-Antitrypsin Gene to the Lung Epithelium in Vivo", Science, 1991, 252, 431-434  105 Rosenfeld, M.A. et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium", Cell., 1992, 68, 143-155  106 Samson, M. et al., "Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene", Nature, 1996, 382, 722-725  107 Samulski, R.J. et al., "Heper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression", J. Virol, 1989, 63,(9), 3822-3828  * 108 SAS Institute, Inc., SAS/STAT Software: Changes and Enhancements through release 6.11. Cary, NC: SAS Institute, Inc.  109 Schultz, L.D. et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus", Gene, 1987, 54, 113-123  110 Seed, B. "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", Nature, 1987, 329, 840-842  EXAMINER		NATE OF THE PERSON NAMED IN COLUMN TO PERSON	TECH CENTER 1600/2900	j	Sheet 11 of 15	
Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office  Patent and Trademark Office  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  101  Reichardt, J.K. V. et al., "Genetic Variability of the Human SRD5A2 Gene: Implications for Prostate Cancer Risk", Cancer Res., 1995, 55, 3973-3975  102  Renier, G. et al., "Lipoprotein Lipase Synergizes with Interferon Gamma to Induce Macrophage Nitric Oxide Synthetase mRNA Expression and Nitric Oxide Production", Arterioscler Thromb. Vasc. Biol., 1995, 15, 392-399  103  Reymer, P. W.A. et al., "A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis", Nat. Genet., 1995, 10, 28-33  104  Rosenfeld, M.A. et al., "Adenovirus-Mediated Transfer of a recombinant S/alpha\$1-Antitrypsin Gene to the Lung Epithelium in Vivo", Science, 1991, 252, 431-434  105  Rosenfeld, M.A. et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium", Cell, 1992, 68, 143-155  106  Samson, M. et al., "Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene", Nature, 1996, 382, 722-725  107  Samulski, R.J. et al, "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression", J. Virol, 1989, 63,(9), 3822-3828  *  108  SAS Institute, Inc., SAS/STAT Software: Changes and Enhancements through release 6.11. Cary, NC: SAS Institute, Inc.  109  Schultz, L.D. et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus", Gene, 1987, 54, 113-123  110  Seed, B. "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", Nature, 1987, 329, 840-842	TRA	Form	•	Docket No.		
Patent and Trademark Office May 3, 2002 Not Yet Assigned  OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)  101 Reichardt, J.K. V. et al., "Genetic Variability of the Human SRD5A2 Gene: Implications for Prostate Cancer Risk", Cancer Res., 1995, 55, 3973-3975  102 Renier, G. et al., "Lipoprotein Lipase Synergizes with Interferon Gamma to Induce Macrophage Nitric Oxide Synthetase mRNA Expression and Nitric Oxide Production", Arterioscler Thromb. Vasc. Biol., 1995, 15, 392-399  103 Reymer, P. W.A. et al., "A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis", Nat. Genet., 1995, 10, 28-33  104 Rosenfeld, M.A. et al., "Adenovirus-Mediated Transfer of a recombinant \$/alpha\$1-Antitrypsin Gene to the Lung Epithelium in Vivo", Science, 1991, 252, 431-434  105 Rosenfeld, M.A. et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium", Cell, 1992, 68, 143-155  106 Samson, M. et al., "Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene", Nature, 1996, 382, 722-725  107 Samulski, R.J. et al, "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression", J. Virol, 1989, 63,(9), 3822-3828  * 108 SAS Institute, Inc., SAS/STAT Software: Changes and Enhancements through release 6.11. Cary, NC: SAS Institute, Inc.  109 Schultz, L.D. et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus", Gene, 1987, 54, 113-123  110 Seed, B. "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", Nature, 1987, 329, 840-842		(	Cited by Applicant			
101 Reichardt, J.K. V. et al., "Genetic Variability of the Human SRD5A2 Gene: Implications for Prostate Cancer Risk", Cancer Res., 1995, 55, 3973-3975  102 Renier, G. et al., "Lipoprotein Lipase Synergizes with Interferon Gamma to Induce Macrophage Nitric Oxide Synthetase mRNA Expression and Nitric Oxide Production", Arterioscler Thromb. Vasc. Biol., 1995, 15, 392-399  103 Reymer, P. W.A. et al., "A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis", Nat. Genet., 1995, 10, 28-33  104 Rosenfeld, M.A. et al., "Adenovirus-Mediated Transfer of a recombinant \$/alpha\$1-Antitrypsin Gene to the Lung Epithelium in Vivo", Science, 1991, 252, 431-434  105 Rosenfeld, M.A. et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium", Cell, 1992, 68, 143-155  106 Samson, M. et al., "Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene", Nature, 1996, 382, 722-725  107 Samulski, R.J. et al, "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression", J. Virol, 1989, 63,(9), 3822-3828  * 108 SAS Institute, Inc., SAS/STAT Software: Changes and Enhancements through release 6.11. Cary, NC: SAS Institute, Inc.  109 Schultz, L.D. et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus", Gene, 1987, 54, 113-123  110 Seed, B. "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", Nature, 1987, 329, 840-842			•	_	-	
Implications for Prostate Cancer Risk", Cancer Res., 1995, 55, 3973-3975  102 Renier, G. et al., "Lipoprotein Lipase Synergizes with Interferon Gamma to Induce Macrophage Nitric Oxide Synthetase mRNA Expression and Nitric Oxide Production", Arterioscler Thromb. Vasc. Biol., 1995, 15, 392-399  103 Reymer, P. W.A. et al., "A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis", Nat. Genet., 1995, 10, 28-33  104 Rosenfeld, M.A. et al., "Adenovirus-Mediated Transfer of a recombinant \$/alpha\$1-Antitrypsin Gene to the Lung Epithelium in Vivo", Science, 1991, 252, 431-434  105 Rosenfeld, M.A. et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium", Cell, 1992, 68, 143-155  106 Samson, M. et al., "Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene", Nature, 1996, 382, 722-725  107 Samulski, R.J. et al., "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression", J. Virol, 1989, 63,(9), 3822-3828  * 108 SAS Institute, Inc., SAS/STAT Software: Changes and Enhancements through release 6.11. Cary, NC: SAS Institute, Inc.  109 Schultz, L.D. et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus", Gene, 1987, 54, 113-123  110 Seed, B. "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", Nature, 1987, 329, 840-842		OTHE	R DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
Macrophage Nitric Oxide Synthetase mRNA Expression and Nitric Oxide Production", Arterioscler Thromb. Vasc. Biol., 1995, 15, 392-399  103 Reymer, P. W.A. et al., "A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis", Nat. Genet., 1995, 10, 28-33  104 Rosenfeld, M.A. et al., "Adenovirus-Mediated Transfer of a recombinant \$/alpha\$1-Antitrypsin Gene to the Lung Epithelium in Vivo", Science, 1991, 252, 431-434  105 Rosenfeld, M.A. et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium", Cell, 1992, 68, 143-155  106 Samson, M. et al., "Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene", Nature, 1996, 382, 722-725  107 Samulski, R.J. et al, "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression", J. Virol, 1989, 63,(9), 3822-3828  * 108 SAS Institute, Inc., SAS/STAT Software: Changes and Enhancements through release 6.11. Cary, NC: SAS Institute, Inc.  109 Schultz, L.D. et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus", Gene, 1987, 54, 113-123  110 Seed, B. "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", Nature, 1987, 329, 840-842		101				
reduced HDL cholesterol levels in premature atherosclerosis", Nat. Genet., 1995, 10, 28-33  104 Rosenfeld, M.A. et al., "Adenovirus-Mediated Transfer of a recombinant \$/alpha\$1-Antitrypsin Gene to the Lung Epithelium in Vivo", Science, 1991, 252, 431-434  105 Rosenfeld, M.A. et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium", Cell, 1992, 68, 143-155  106 Samson, M. et al., "Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene", Nature, 1996, 382, 722-725  107 Samulski, R.J. et al, "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression", J. Virol, 1989, 63,(9), 3822-3828  * 108 SAS Institute, Inc., SAS/STAT Software: Changes and Enhancements through release 6.11. Cary, NC: SAS Institute, Inc.  109 Schultz, L.D. et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus", Gene, 1987, 54, 113-123  110 Seed, B. "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", Nature, 1987, 329, 840-842		102	Macrophage Nitric Oxide Synthetase	mRNA Expression an	d Nitric Oxide	
Antitrypsin Gene to the Lung Epithelium in Vivo", Science, 1991, 252, 431-434  105 Rosenfeld, M.A. et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium", Cell, 1992, 68, 143-155  106 Samson, M. et al., "Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene", Nature, 1996, 382, 722-725  107 Samulski, R.J. et al, "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression", J. Virol, 1989, 63,(9), 3822-3828  * 108 SAS Institute, Inc., SAS/STAT Software: Changes and Enhancements through release 6.11. Cary, NC: SAS Institute, Inc.  109 Schultz, L.D. et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus", Gene, 1987, 54, 113-123  110 Seed, B. "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", Nature, 1987, 329, 840-842		103	reduced HDL cholesterol levels in pr	•	•	
Transmembrane Conductance Regulator Gene to the Airway Epithelium", Cell, 1992, 68, 143-155  106 Samson, M. et al., "Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene", Nature, 1996, 382, 722-725  107 Samulski, R.J. et al, "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression", J. Virol, 1989, 63,(9), 3822-3828  * 108 SAS Institute, Inc., SAS/STAT Software: Changes and Enhancements through release 6.11. Cary, NC: SAS Institute, Inc.  109 Schultz, L.D. et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus", Gene, 1987, 54, 113-123  110 Seed, B. "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", Nature, 1987, 329, 840-842		104	•		-	
mutant alleles of the CCR-5 chemokine receptor gene", Nature, 1996, 382, 722-725  107 Samulski, R.J. et al, "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression", J. Virol, 1989, 63,(9), 3822-3828  * 108 SAS Institute, Inc., SAS/STAT Software: Changes and Enhancements through release 6.11. Cary, NC: SAS Institute, Inc.  109 Schultz, L.D. et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus", Gene, 1987, 54, 113-123  110 Seed, B. "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", Nature, 1987, 329, 840-842		105	Transmembrane Conductance Regula	•		
Normal Integration Does Not Require Viral Gene Expression", J. Virol, 1989, 63,(9), 3822-3828  * 108 SAS Institute, Inc., SAS/STAT Software: Changes and Enhancements through release 6.11. Cary, NC: SAS Institute, Inc.  109 Schultz, L.D. et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus", Gene, 1987, 54, 113-123  110 Seed, B. "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", Nature, 1987, 329, 840-842		106			_	
<ul> <li>6.11. Cary, NC: SAS Institute, Inc.</li> <li>Schultz, L.D. et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus", Gene, 1987, 54, 113-123</li> <li>Seed, B. "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", Nature, 1987, 329, 840-842</li> </ul>		107	Normal Integration Does Not Require Viral Gene Expression", J. Virol, 1989, 63,(9),			
glycoprotein derived from Epstein-Barr virus", Gene, 1987, 54, 113-123  110 Seed, B. "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2", Nature, 1987, 329, 840-842	*	108				
homologous to its receptor CD2", Nature, 1987, 329, 840-842		109				
EXAMINER DATE CONSIDERED	•	110				
	EXAM	INER		DATE CONSIDER	ED	

OCT 0 2 2002

Sheet 12 of 15

Form Form	PTO-1449 MEGHCENTER 1600/29	OPocket No. SMAR-0013	Serial No. 10/019,341					
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Hayden, M.R. et al.						
	Department of Commerce and Trademark Office	Filing Date May 3, 2002	Group Not Yet Assigned					
ОТНЕ	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
111	Sing, K. et al., "Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events Lipoprotein and Coronary Atherosclerosis Study", <i>Atherosclerosis</i> , 1999, 144, 435-442							
112	Smith, T.F. et al., "Comparasion of Biosequences", Adv. Appl. Math., 1981, 2, 482-489							
113	Smith, G.E. et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vecotr", <i>Mol. Cell. Biol.</i> , <b>1983</b> , 3(12), 2156-2165							
114	Sparkes, R.S. et al., "Human Genes Involved in Lipolysis of Plasma Lipoproteins: Mpping of Loci for Lipoprotein Lipase to 8p22 and Hepatic Lipase to 15q21", Genomics, 1987, 1(2), 138-144							
115	Steinberg, H.O. MD., "Endothelial Dysfunction is Associated with Cholesterol Levels in the High Normal Range in Humans", <i>Circulation</i> , <b>1997</b> , 96(10), 3287-3293							
116	Stocks, J. et al., "Lipoprotein lipase genotypes for a common premature termination codon mutation detected by PCR-mediated site-directed mutagenesis and restriction digestion", J. Lipid. Res., 1992, 33, 853-857							
117	Strauss, J.G. et al., "Generation of adult LPL-deficeint mice", Atherosclerosis, 2000, 151, 158 (abstract)							
118	Stroes, E. et al., "NO activity in familial combined hyperlipidemia: potential role of cholesterol remnants", <i>Cardiovasc. Res.</i> , <b>1997</b> , 36, 445-452							
. 119	Taskinen, M-R. Et al., "High density lipoprotein subfractions in relation to lipoprotein lipase activity of tissues in man-evidence for reciprocal regulation of HDL2 and HDL3 levels by lipoprotein lipase", Clin. Chim. Act., 1981, 112, 325-332							
120	Tratschin, J-D. et al., "Genetic Analysis of Adeno-Associated Virus: Properties of Deletion Mutants Constructed in Vitro and Evidence for an Adeno-Associated Virus Replication Function", J. Virol., 1984, 51(3), 611-619							
EXAMINER DATE CONSIDERED								

OCT 0 2 2002

Sheet 13 of 15

Form PTO-1449 Modified 1600/2900 ocket No. Serial No. **SMAR-0013** 10/019,341 List of Patent and Publications Applicant Cited by Applicant Hayden, M.R. et al. (Use several sheets if necessary) U.S. Department of Commerce Filing Date Group May 3, 2002 Patent and Trademark Office Not Yet Assigned OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Tratschin, J-D., et al., "Adeno-Associated Virus Vector for High Frequency 121 Integration, Expression, and Rescue of Genes in Mammalian Cells", Mol. Cell. Biol., 1985, 5, 3251-3260 122 Tratschin, J-D. et al., "A Human Parovirus, Adeno-Associated Virus, as a Eucaryotic Vector: Transient xpression and Encapsidation of the Procaryotic Gene for Chloramphenicol Acetyltransferase", Mol. Cell. Biol., 1985, 4, 2072-2081 123 Van Beuschem, V.W. et al., "Long-Term Expression of Human Adenosine Deaminas in Rhesus Monkeys Transplanted with Retrovirus-Infected Bone-Marrow Cells", Proc. Natl. Acad. Sci. USA, 1992, 89(16), 7640-7644 Vogel, R.A., MD. et al., "Effect of a Single High-Fat Meal on Endothelial Function in 124 Healthy Subjects", Am. J. Cardiol., 1997, 79, 350-354 Weinstock, P.H. et al., "Severe Hypertiglyceridemia, Reduced High Density 125 Lipoprotein, and Neonatal Death in Lipoprotein Lipase Knockout Mice", J. Clin. Invest., 1995, 96, 2555-2568 Wess, G. et al., "Modified Bile Acids:Preparation of 7α, 12α-Dihydroxy-3β- and 7α, 126 12α-Dihydroxy-3-α-(2-Hydroxyethoxy)-5β-Cholanic Acid and Their Biological Activity", Tetrahedron Letters, 1992, 33, 195-198 Wess, G. et al., "Preparation of 3α-and 3β-(w-Aminoalkoxy)-7α, 12α-Dihydroxy-5β-127 Cholanoic Acid Esters: Versatile Shuttles for Drug Targeting", Tetrahedron Letters, 1992, 34(5), 817-822 Wilcox, J.N. et al., "Expression of Multiple Isoforms of Nitric Oxide Synthase in 128 Normal and Atherosclerotic Vessels", Arterioscler. Thromb. Vasc. Biol., 1997, 17(11), 2479-2488 Wilson, et al., "Prevalence of Coronary Heart Disease in the Framingham Offspirng 129 Study: Role of Lipoprotein Cholesterols", Am. J. Cardiol., 1980, 46, 649-654 Wilson, J.M. et al., "Retrovirus-Mediated Transductions of Adult Hepatocytes", Proc. 130 Natl. Acad. Sci. USA., 1988, 85(9), 3014-3018 **EXAMINER DATE CONSIDERED** 

OCT 0 2 2002

**TECH CENTER 1600/2900** 

Sheet 14 of 15

		12011 0211121(10	00/2300	Sneet 14 of 15		
PRADEMARK	Form	PTO-1449 Modified	Docket No. SMAR-0013	Serial No. 10/019,341		
	(	f Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Hayden, M.R. et al.			
	U.S. Department of Commerce Patent and Trademark Office		Filing Date May 3, 2002	Group Not Yet Assigned		
	ОТНЕ	R DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)		
	131	Wilson, J.M. et al., "Hepatocyte-direct Improvement of Hypercholesterolement deficient Rabbits", J. Biol. Chem., 19	ia in Low Density Lipo			
	132	Wion, K.L. et al. "Human Lipoprotein Science, 1987, 235(4796), 1638-1641		ary DNA Sequence",		
	133	Wittrup, H. H. et al., "A Common Substitution (Asn291Ser) in Lipoprotein Lipase is Associated with Increased Risk of Ischemic Heart Disease", J. Clin. Invest., 1997, 99(7), 1606-1613				
	134	Wittrup, H.H. MD, PhD. et al., "Lipo Lipoproteins, and Risk of Ischemic H 1999, 99(22), 2901-2907	-			
	135	Wolff, J.A. et al., "Direct Gene Trans 247(4949), 1465-1468	fer into Mouse Muscle	e in Vivo", Science, 1990,		
	136	Wondisford, F.E. et al., "cloning of the Human Thyrotropin β-Subunit Gene and Transient Expression of Biologically Active Human Thyrotropin after Gene Transfection", <i>Mol. Endocrinol.</i> , <b>1988</b> , 2, 32-39				
	137	Wu, G.Y. et al., "Receptor-mediated Chem., 1988, 263(29), 14621-14624	Gene Delivery and Ex	pression in Vivo", J. Biol.		
	138	Zechner, R. "The tissue-specific expression of lipoprotein lipase: implications for energy and lipoprotein metabolism", Curr. Opin. Lipidol., 1997, 8(2), 77-88				
	139	Zhang, H. et al., "Patients with ApoE3 Deficiency (E2/2, E3/2, and E4/2) Who Manifest with Hyperlipidemia Have Increased Frequency of an Asn 291- Ser Mutation in the Human LPL Gene", <i>Arterioscler. Thromb. Vasc. Biol.</i> , <b>1995</b> , 15(10), 1695-1703				
	140	Zhang, H. et al., "Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function", <i>Biochimica et Biophysica Acta</i> , 1996, 1302, 159-166				
	141	Kastelein JJP., et al. "The Asn9 variant of lipoprotein lipase is associated with the- 93 G promoter mutation and an increased risk of coronary artery disease", <i>Clin Genet</i> , 1998, 53, 27-33				
EXAMINI	ER		DATE CONSIDER	ED		
L						

OCT 0 2 2002

RED 3 11 JULI			OCT 0 2 200	_		Sheet 15 of 15
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)				4900ket No. SMAR-0013	Serial No. 10/019,341	
				Applicant Hayden, M.R. et al.		
U.S. Department of Commerce Patent and Trademark Office			Filing Date May 3, 2002	Group Not Yet Assigned		
		U. S	. PATENT DO	CUMENTS		
Examiner Initial		Document No.	Date	Name	Class	Subclass
	142	4,554,101	11/19/85	Норр	260	112.5
	143	4,868,116	09/19/89	Norgan, et al.	435	240.2
	144	4,980,286	12/25/90	Morgan, et al.	435	172.3
-	145	5,166,320	11/24/92	Wu, et al.	530	395
	146	5,399,346	03/21/95	Anderson, et al.	424	93.21
	147	5,658,729	08/19/97	Hayden, et al.	435	6
		FOREI	GN PATENT I	DOCUMENTS		<u> </u>
Examiner Initial		Document No.	Date	Country	Translation YES NO	
	148	WO 89/07136	08/10/89	PCT		
	149	WO 89/02468	03/23/89	PCT		
	150	WO 89/05345	06/15/89	PCT		
	151	WO 92/07573	05/14/92	PCT		
•	152	WO 95/05452	02/23/95	PCT		
	153	WO 95/27512	10/19/95	PCt .		

DATE CONSIDERED

**EXAMINER**